What type of study is this?

Treat‐To‐Target: Emergence of Second‐Generation CD40L Inhibitors for Treatment of SLE—Identifying Beneficial Patient Candidates for CD40L Inhibitors in a Cross‐Sectional SLE Cohort

View Full Paper

Ask AI

Bookmark

Authors

Cross-sectional analysis shows elevated sCD40L as a potential biomarker in SLE patients, suggesting targeted therapy implications.

Elevated plasma levels of sCD40L in SLE patients correlate with disease activity and severity markers, indicating its potential role in treatment strategies.
SLE patients showed significant differences in sCD40L levels compared to healthy controls, with medians of 2.2 ng/mL and 0.81 ng/mL, respectively.
Analysis utilized k-means clustering and principal component analysis to reveal patterns in disease activity linked to sCD40L levels.
The findings highlight the need for longitudinal studies to validate sCD40L's role as a biomarker for personalized SLE treatment.

Pedersen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark